Latest Safety News

Black Cat Syndicate reports robust operational progress at its Kal East Gold Operation, surpassing expectations at the Lakewood processing facility and achieving early cash flow positivity at the Myhree open pit. Development activities at Majestic and Fingals advance as the company expands production capacity.

Life360 has increased its convertible notes offering to $275 million, introducing capped call transactions to manage dilution risks as it prepares for potential growth investments.

InhaleRx has secured swift Human Research Ethics Committee approval for its redesigned IRX-211 Phase 2 trial, expanding participant numbers and potentially bypassing Phase 3 to speed market entry.

Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.

Life360 has announced a $250 million convertible senior notes offering, with an option for an additional $37.5 million, aiming to bolster its balance sheet and support strategic initiatives.

Lincoln Minerals reports breakthrough metallurgical results from its Kookaburra Graphite Project, achieving ultra-high purity graphite suitable for lithium-ion battery anodes without using hazardous hydrofluoric acid. This advance supports the company’s downstream processing ambitions in South Australia.

Ioneer Ltd has announced a 308% increase in the Ore Reserve for its Rhyolite Ridge Lithium-Boron Project in Nevada, extending mine life to 95 years and confirming robust economics with low-cost lithium production and a stable boric acid revenue stream.

Tasmea Limited is set to acquire the Vertex Group, enhancing its high voltage and portable power services across regional Australia, with a deal expected to boost earnings per share by 3%.

HITIQ has secured a pivotal one-year deal with the South Metro Junior Football League, positioning its PROTEQT concussion management system at the heart of junior sports safety. This move complements existing partnerships and signals a strong push into Australia’s grassroots sports market.

Neurotech International has reported positive human pharmacokinetic results for NTI164, a cannabinoid formulation designed for paediatric neurological disorders, confirming rapid absorption and a non-intoxicating profile.

Radiopharm Theranostics has unveiled encouraging preclinical results for its Lu177-B7H3 monoclonal antibody, RV01, paving the way for a mid-2025 Investigational New Drug submission and a Phase 1 trial later that year.

Vection Technologies has landed a $1 million contract to enhance cyber and data protection for national security intelligence, extending its footprint in the defence sector. This deal builds on previous engagements and signals potential for further growth.